S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital

Cytokinetics (CYTK) Stock Forecast, Price & News

$37.36
-0.18 (-0.48%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$37.06
$37.92
50-Day Range
$33.36
$40.75
52-Week Range
$32.96
$55.80
Volume
371,600 shs
Average Volume
945,020 shs
Market Capitalization
$3.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.29

Cytokinetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
50.7% Upside
$56.29 Price Target
Short Interest
Bearish
10.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.49mentions of Cytokinetics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$3.59 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.46) to ($4.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

253rd out of 1,010 stocks

Pharmaceutical Preparations Industry

107th out of 494 stocks


CYTK stock logo

About Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Stock News Headlines

Cytokinetics (NASDAQ:CYTK) Upgraded at StockNews.com
Cytokinetics (CYTK) Gets a Buy from Mizuho Securities
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
What 20 Analyst Ratings Have To Say About Cytokinetics
JMP Securities Remains a Buy on Cytokinetics (CYTK)
H.C. Wainwright Sticks to Its Buy Rating for Cytokinetics (CYTK)
Goldman Sachs Remains a Buy on Cytokinetics (CYTK)
The One Ticker Retirement Plan Over the Shoulder Demo Now Available
Market Wizard Larry Benedict crushed the market in 2022. But he hasn’t done it with a “traditional” method… For a limited time, he’s sharing a free over-the-shoulder “demo” of his strategy in action.
StockNews.com Lowers Cytokinetics (NASDAQ:CYTK) to Sell
Cytokinetics (NASDAQ:CYTK) Downgraded by StockNews.com
Cytokinetics (NASDAQ:CYTK) PT Raised to $62.00
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Company Calendar

Last Earnings
5/04/2023
Today
5/29/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
253
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$56.29
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+50.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

Net Income
$-388,950,000.00
Net Margins
-439.05%
Pretax Margin
-439.35%

Debt

Sales & Book Value

Annual Sales
$94.59 million
Book Value
($1.14) per share

Miscellaneous

Free Float
92,007,000
Market Cap
$3.57 billion
Optionable
Optionable
Beta
0.80

Social Links


Key Executives

  • Robert I. BlumRobert I. Blum
    President, Chief Executive Officer & Director
  • Eric Terhaerdt
    Vice President-Development Operations
  • Ching W. JawChing W. Jaw
    Chief Financial Officer & Senior Vice President
  • Fady Ibraham MalikFady Ibraham Malik
    Executive Vice President-Research & Development
  • Andy Wolff
    Senior VP-Clinical Research & Development













CYTK Stock - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price forecast for 2023?

12 analysts have issued 12-month target prices for Cytokinetics' stock. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they anticipate the company's share price to reach $56.29 in the next twelve months. This suggests a possible upside of 50.7% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2023?

Cytokinetics' stock was trading at $45.82 at the beginning of the year. Since then, CYTK shares have decreased by 18.5% and is now trading at $37.36.
View the best growth stocks for 2023 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by $0.14. The biopharmaceutical company earned $4.60 million during the quarter, compared to analysts' expectations of $2.50 million. Cytokinetics had a negative net margin of 439.05% and a negative trailing twelve-month return on equity of 1,401.63%. The company's quarterly revenue was up 300.0% on a year-over-year basis. During the same period last year, the company posted ($1.02) earnings per share.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $5.00 million-$5.00 million.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.29%), FMR LLC (13.45%), Wellington Management Group LLP (7.87%), State Street Corp (4.97%), American Century Companies Inc. (2.80%) and Pictet Asset Management SA (2.38%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $37.36.

How much money does Cytokinetics make?

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.57 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns $-388,950,000.00 in net income (profit) each year or ($4.58) on an earnings per share basis.

How many employees does Cytokinetics have?

The company employs 253 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.

This page (NASDAQ:CYTK) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -